Business
Ardelyx Launching IBSRELA® Second Quarter of 2022
- IBSRELA (tenapanor) the first and only NHE3 inhibitor approved for treatment of IBS-C in adults - IBSRELA potential peak net revenue greater than $500
About this update from Ardelyx, Inc.
[{"type":"text","content":"- IBSRELA (tenapanor) the first and only NHE3 inhibitor approved for treatment of IBS-C in adults\n - IBSRELA potential peak net revenue greater than $500 million annually\n - Large and established IBS-C market in need of new therapeutic options\n - Small specialty sales organization and focused digital marketing to target high prescribers and dissatisfied patients\n - Company continues to pursue approval of tenapanor in hyperphosphatemia\n - Company to host conference call today at 8:00 AM ET\n\n\nFREMONT, Calif. and WALTHAM, Mass., Nov. 30, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialty biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced plans to launch IBSRELA, the company's approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022. \n\n \n \n \n \n \n \n\n \nMike Raab, president and chief executive officer of Ardelyx, stated, \"Over the last five years, the IBS-C market has grown to be sizeable and concentrated, with 9,000 high-writing physicians accounting for approximately 50% of the almost five million prescriptions written annually for drugs indicated for the treatment of IBS-C. This market is ripe for the entry of a novel therapeutic option like IBSRELA, as existing therapies do not adequately address all patient treatment needs. Our market research has clearly shown that treating physicians recognize the need for new therapeutic alternatives to address the unmet medical needs of patients currently managed for IBS-C. That same research demonstrates high interest in, and intent to prescribe, IBSRELA for a subset of patients. By capturing even a modest share, in the mid to high single-digit of this large market, IBSRELA has the potential to generate at least $500 million in peak annual net revenue. We will use the next few months to build commercial inventory and prepare the market for a second-quarter 2022 launch. We believe we have a clear line of sight to breakeven and ultimate profitability for the product, which we expect will create significant shareholder value.\" \nWilliam Chey, M.D., Nostrant Professor of Medicine at the University of Michigan School of Medicine, added, \"It is now widely recognized that while pe...